Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
CordenPharma, GE form oligonucleotide services pact
by Rick Mullin
July 17, 2017
| A version of this story appeared in
Volume 95, Issue 29
CordenPharma International and GE Healthcare’s Dharmacon division are joining to provide what they call an end-to-end service for oligonucleotide-based drug discovery. The GE unit offers custom synthesis of complex oligos to support research. CordenPharma provides larger-scale oligos manufacturing, a service it launched last year after investing in a Boulder, Colo., plant it acquired from Roche in 2011. CordenPharma currently supports early-stage clinical development and expects to begin commercial-scale manufacturing by the end of the year.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter